Meta-Analysis of Bioprosthetic Valve Thrombosis after Transcatheter Aortic Valve Implantation.

[1]  Jeroen J. Bax,et al.  Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves: PARTNER 3 Cardiac Computed Tomography Substudy. , 2020, Journal of the American College of Cardiology.

[2]  M. Mack,et al.  Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. , 2020, The New England journal of medicine.

[3]  C. Hengstenberg,et al.  Hemodynamic structural valve deterioration following transcatheter aortic valve implantation with latest-generation balloon-expandable valves. , 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[4]  C. Terkelsen,et al.  Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. , 2019, The New England journal of medicine.

[5]  J. Tijssen,et al.  A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. , 2019, The New England journal of medicine.

[6]  F. Nietlispach,et al.  Incidence, predictors and cerebrovascular consequences of leaflet thrombosis after transcatheter aortic valve implantation: a systematic review and meta-analysis. , 2019, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[7]  J. Leipsic,et al.  Transcatheter Aortic‐Valve Replacement with a Balloon‐Expandable Valve in Low‐Risk Patients , 2019, The New England journal of medicine.

[8]  Andrew S. Mugglin,et al.  Transcatheter Aortic‐Valve Replacement with a Self‐Expanding Valve in Low‐Risk Patients , 2019, The New England journal of medicine.

[9]  M. Mack,et al.  Clinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves by Four-Dimensional Computed Tomography. , 2018, The Annals of thoracic surgery.

[10]  F. Neumann,et al.  Medium-Term Follow-Up of Early Leaflet Thrombosis After Transcatheter Aortic Valve Replacement. , 2018, JACC. Cardiovascular interventions.

[11]  L. Räber,et al.  Transcatheter aortic valve thrombosis: incidence, clinical presentation and long-term outcomes , 2018, European heart journal cardiovascular Imaging.

[12]  H. Rashid,et al.  Bioprosthetic aortic valve leaflet thrombosis detected by multidetector computed tomography is associated with adverse cerebrovascular events: a meta-analysis of observational studies. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[13]  S Achenbach,et al.  Leaflet thrombosis following transcatheter aortic valve implantation. , 2017, Journal of cardiovascular computed tomography.

[14]  V. Letocart,et al.  Could anticoagulation avoid bioprosthesis subclinical thrombosis in patients undergoing transcatheter aortic valve replacement? , 2018, Archives of cardiovascular diseases.

[15]  B. Prendergast,et al.  Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Societ , 2017, European heart journal.

[16]  Wen Cheng,et al.  Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study , 2017, The Lancet.

[17]  Jeroen J. Bax,et al.  Transcatheter aortic valve thrombosis: the relation between hypo-attenuated leaflet thickening, abnormal valve haemodynamics, and stroke , 2017, European heart journal.

[18]  G. Richardt,et al.  Clinical Bioprosthetic Heart Valve Thrombosis After Transcatheter Aortic Valve Replacement: Incidence, Characteristics, and Treatment Outcomes. , 2017, JACC. Cardiovascular interventions.

[19]  O. Alfieri,et al.  Single-Antiplatelet Therapy in Patients with Contraindication to Dual-Antiplatelet Therapy After Transcatheter Aortic Valve Implantation. , 2017, The American journal of cardiology.

[20]  G. Richardt,et al.  Comparison of dual antiplatelet therapy versus oral anticoagulation following transcatheter aortic valve replacement: A retrospective single-center registry analysis. , 2017, Cardiology journal.

[21]  A. Ducci,et al.  Transcatheter aortic valves produce unphysiological flows which may contribute to thromboembolic events: An in-vitro study , 2016, Journal of biomechanics.

[22]  C. Terkelsen,et al.  Transcatheter Aortic Valve Thrombosis: Incidence, Predisposing Factors, and Clinical Implications. , 2016, Journal of the American College of Cardiology.

[23]  M. Hernán,et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.

[24]  J. Leipsic,et al.  Early hypo-attenuated leaflet thickening in balloon-expandable transcatheter aortic heart valves. , 2016, European heart journal.

[25]  M. Jinzaki,et al.  Incidence, Predictors, and Mid-Term Outcomes of Possible Leaflet Thrombosis After TAVR. , 2016, JACC. Cardiovascular imaging.

[26]  Deepak L. Bhatt,et al.  Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. , 2015, The New England journal of medicine.

[27]  J. Leipsic,et al.  Early Aortic Transcatheter Heart Valve Thrombosis: Diagnostic Value of Contrast-Enhanced Multidetector Computed Tomography , 2015, Circulation. Cardiovascular interventions.

[28]  O. Alfieri,et al.  Treatment and Clinical Outcomes of Transcatheter Heart Valve Thrombosis , 2015, Circulation. Cardiovascular interventions.

[29]  Robert L Grant,et al.  Converting an odds ratio to a range of plausible relative risks for better communication of research findings , 2014, BMJ : British Medical Journal.

[30]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.